Candesartan for Prevention of Cardiovascular Events After Cypher or Taxus Coronary Stenting (4C) Trial

NCT00139386 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

1119

Enrollment

OTHER

Sponsor class

Conditions

Hypertension
Coronary Artery Disease

Interventions

DRUG: Candesartan

Sponsor

Kumamoto University

Collaborators

[object Object]
[object Object]